肥厚型心肌病的药物治疗进展  

Drug Treatment of Hypertrophic Cardiomyopathy

作　　者：普露桐 陈玉成[1,2] PU Lutong;CHEN Yucheng(Department of Cardiology,West China Hospital of Sichuan University,Chengdu 610041,Sichuan,China;Center of Rare Diseases,West China Hospital of Sichuan University,Chengdu 610041,Sichuan,China)

机构地区：[1]四川大学华西医院心脏内科,四川成都610041 [2]四川大学华西医院罕见病中心,四川成都610041

出　　处：《心血管病学进展》2024年第2期107-110,共4页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金青年科学基金(82202248);四川省自然科学基金青年基金(23NSFSC4589);四川大学华西医院1·3·5临床研究基金(2023HXFH041)。

摘　　要：肥厚型心肌病(HCM)是最常见的遗传性心肌病,特点是左心室肥大、心肌过度收缩及舒张功能障碍。HCM的治疗药物选择有限,包括β受体阻滞剂、钙通道阻滞剂。这些药物不能阻止自然病程进展,也不能有效降低并发症的发生率。近年来,对HCM遗传基础和病理生理机制的了解不断加深,开发了靶向的、可能改善疾病的疗法。现结合最新研究进展,系统地阐述该病的药物治疗。Hypertrophic cardiomyopathy(HCM)is the most common inherited cardiomyopathy and is characterized by left ventricular hypertrophy,myocardial hypercontraction,and diastolic dysfunction.Drug treatment options of HCM are limited,including beta blockers,calcium channel blockers.These drugs do not prevent progression of the natural history and are not effective in reducing the incidence of complications.In recent years,increased knowledge of the genetic basis and pathophysiological mechanisms of HCM has led to the development of targeted,potentially disease-modifying therapies.In this article,we systematically describe the drug treatment of this disease based on the latest research progress.

关 键 词：肥厚型心肌病 药物治疗 肌球蛋白抑制 

分 类 号：R542.2[医药卫生—心血管疾病]